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Abstract: Treatment options for HIV patients have dramatically improved since the introduction 
of efﬁ  cacious antiretroviral combination therapy more than a decade ago. Treatment regimens 
have been simpliﬁ  ed with fewer pills and fewer daily dosages. Fosamprenavir is a protease 
inhibitor with a rather long half-life which makes it a candidate for once-daily use. Once-daily 
dosage of ritonavir-boosted fosamprenavir is approved in the US, but not in Europe, for treatment 
in patients without prior antiretroviral treatment. Here we review the background and rationale 
for once-daily dosage of ritonavir-boosted fosamprenavir. The rather limited studies that have 
been published so far indicate that fosamprenavir 1400 mg may be used once daily boosted 
with ritonavir. The optimal ritonavir dose to be given together with fosamprenavir is still to be 
deﬁ  ned, though available results indicate that a dose of 100 mg may be adequate provided that 
no protease inhibitor resistance is present.
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Introduction
Antiretroviral drug combinations including two nucleoside reverse transcriptase 
inhibitors (NRTI) and a protease inhibitor (PI) were introduced in the mid 1990s. 
These drug combinations provided potent options for HIV-infected patients to durably 
suppress HIV to undetectable levels and dramatically reduced morbidity and mortality 
in HIV infection. Complicated dosing regimens and food restrictions had initially a 
negative impact on adherence and quality of life. A major improvement was achieved 
with the principle of boosting by administrating PIs together with a low dose of rito-
navir to improve pharmacokinetic properties, making more convenient dosing options 
possible and thus improving adherence and virological outcome. At the present time 
eight different PIs are licensed in the US and Europe. With the exception of nelﬁ  navir 
all PIs (indinavir, saquinavir, lopinavir, fosamprenavir, atazanavir, tipranavir, and 
darunavir) can or should be used together with low dose ritonavir.
Once-daily dosing of protease inhibitors
Only atazanavir is exclusively licensed for once-daily use. However, a number of stud-
ies have been performed in which other PIs have been evaluated in once-daily regimens. 
In a recent study lopinavir/r was given once or twice daily together with co-formulated 
tenofovir/emtricitabine in treatment-naïve patients. After 48 weeks lopinavir/r given 
once daily was shown to be non-inferior to twice-daily therapy (Gathe et al 2008).
Also darunavir/r given once daily to treatment-naïve patients has been studied. In the 
Artemis study it was compared to lopinavir/r (given once or twice daily) and was shown 
to be non-inferior. The darunavir/r dose was 800 mg together with 100 mg ritonavir. Therapeutics and Clinical Risk Management 2008:4(6) 1282
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Also in this study the nucleoside backbone was co-formulated 
tenofovir/emtricitabine (Ortiz et al 2008).
The Gemini Study was a 48-week trial that randomized 
337 treatment-naïve patients to either saquinavir/r or 
lopinavir/r, together with two NRTIs. The old capsule formu-
lation of lopinavir/r was used twice daily and the saquinavir 
dose was 1000 mg together with 100 mg ritonavir. The NRTI 
backbone was tenofovir/emtricitabine. No statistically sig-
niﬁ  cant differences were found between the 2 regimens after 
48 weeks treatment (Walmsley et al 2007).
In the US, once-daily use of ritonavir-boosted lopinavir 
and fosamprenavir are licensed and recommended as alter-
native PIs in patients without prior antiretroviral treatment 
(Panel on Antiretroviral Guidelines for Adults and Adoles-
cents 2008). FDA has approved both 100 and 200 mg of 
ritonavir once daily together with 1400 mg fosamprenavir. 
In Europe neither lopinavir/r nor fosamprenavir/r are licensed 
for use once daily. Despite this, The European AIDS Clinical 
Society (EACS) guidelines 2007 recommend lopinavir/r, 
fosamprenavir/r, and saquinavir/r given once daily as alterna-
tives for treatment-naïve patients in combination with two 
NRTIs (Clumeck et al 2008).
Treatment with fosamprenavir/r
The PI amprenavir was approved by the FDA 1999. Because 
amprenavir has low water solubility, a high rate of excipients 
to drug is required leading to large pills and a limited amount 
of drug in each pill, and a dose of 8 large pills twice daily. 
The use of amprenavir was limited by the large pill size and 
high pill burden. To overcome these obstacles the pro-drug 
fosamprenavir was developed. It is a phosphate ester pro-drug 
of amprenavir with improved water solubility, making it 
possible to make smaller pills with more active drug in each 
pill and allowing more convenient dosage. Fosamprenavir 
is metabolized to amprenavir in the epithelial cells of the 
intestine. The pro-drug itself is not substantially absorbed 
and the systemic exposure to fosamprenavir is low (Furﬁ  ne 
et al 2004).
A 6-week, randomized, controlled, double-blind and 
crossover study in treatment-naïve HIV-positive patients 
showed that fosamprenavir delivered similar amprenavir 
concentrations compared to standard-dose amprenavir 
(Wood et al 2004).
Amprenavir has a terminal half-life of 8 hours (Sadler 
et al 1999) and it is metabolized principally by P450 CYP 
3A4. Boosting with ritonavir increases AUC and Cmin of 
amprenavir using a non-compartmental pharmacokinetic 
method (Sadler et al 2001).
The NEAT study was a 48-week study in treatment-naïve 
patients randomized to either non-boosted fosamprenavir 
1400 mg bid or 1250 mg nelﬁ  navir bid with a backbone in 
both arms of abacavir/lamivudine. The randomization was 2:1 
with 166 patients receiving fosamprenavir and 83 nelﬁ  navir. 
Sixty-six percent of the patients on fosamprenavir versus 
51% on nelﬁ  navir had viral loads below 400 copies/mL. 
Diarrhea was signiﬁ  cantly more common in the nelﬁ  navir 
group. This was the only signiﬁ  cant difference found in side 
effects (Rodriguez-French et al 2004).
Ritonavir-boosted fosamprenavir was compared to 
boosted lopinavir in the KLEAN study, a large non-inferiority 
study in treatment-naïve patients that enrolled 837 patients. 
Patients were randomized to either boosted lopinavir in 
standard dose twice daily or fosamprenavir 700 mg twice 
daily together with 100 mg ritonavir twice daily. All patients 
received background therapy of abacavir together with 
lamuvidine. After 48 weeks, non-inferiority was shown for 
fosamprenavir/r, 73% of patients achieving viral load below 
400 copies for fosamprenavir/r versus 71% for lopinavir/r. 
In summary there were no differences in efﬁ  cacy, tolerability, 
or safety between the two treatments (Eron et al 2006). 
Similar results were reported in an open-label, observational 
study on 82 therapy-naïve HIV-infected subjects followed 
for 18 months (Calza et al 2008).
Fosamprenavir administered 
once daily
As stated above, because amprenavir has a rather long 
half-life once-daily therapy is feasible. The SOLO study 
compared once-daily fosamprenavir with 200 mg ritonavir 
and nelﬁ  navir given twice daily. Abacavir and lamuvidine 
were given twice daily to patients in both treatment arms. 
A total of 649 patients were enrolled. At 48 weeks 69% 
achieved viral load below 400 copies and 55% below 
50 copies in the fosamprenavir/r arm. The corresponding 
ﬁ  gures for nelﬁ  navir were 68% and 53%. Viral failure 
occurred in 17% of nelﬁ  navir patients versus 7% in patients 
receiving fosamprenavir/r. Diarrhea was signiﬁ  cantly more 
common in patients receiving nelﬁ  navir. Total cholesterol 
increased 38% and 37%, respectively, in the two treatment 
groups. In summary the virological results were somewhat 
disappointing with 55% and 53% reaching viral load below 
50 copies. No genotypic resistance mutations to amprenavir 
were however detected (Gathe et al 2004).
Even at low doses, ritonavir causes lipid elevations and 
gastrointestinal side effects (Cooper et al 2003). To explore 
the possibilities of further reducing the dose of ritonavir Therapeutics and Clinical Risk Management 2008:4(6) 1283
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in once-daily fosamprenavir therapy, a pharmacokinetic 
crossover study in 36 healthy volunteers was performed 
(Ruane et al 2007). Fosamprenavir was given once daily 
at 1400 mg together with either 100 or 200 mg of ritonavir 
during 14 days. After a washout period of 21 to 28 days 
medication was resumed for another 14 days with the 
alternate ritonavir dose. Steady state plasma amprenavir 
concentrations were measured at day 14 of each medication 
cycle. Equivalence between regimens for Cmax and AUC of 
the two ritonavir doses were shown. Cmin was 38% lower for 
those receiving 100 mg of ritonavir. The Cmin was, however, 
2.5 times higher than the Cmin that is achieved with unboosted 
fosamprenavir 1400 mg twice daily, which is an approved 
dose in the US. Based on these observations a treatment 
study was initiated comparing once-daily fosamprenavir in 
treatment-naïve patients with either 100 or 200 mg ritonavir 
during 96 weeks; 115 patients were included (Hicks et al 
2007). Interim results after 48 weeks show that 79% of 
patients in the 100 mg group compared to 63% in the 200 mg 
group had viral loads less than 50 copies/mL. The virological 
efﬁ  cacy was higher in the 100 mg group but there were no 
tolerability or lipid advantages observed with the lower rito-
navir dose. Both the improved virological response and the 
absence of tolerability and lipid advantages may be explained 
by differences in adherence. The adherence was estimated to 
be higher in the 100 mg ritonavir arm. In another random-
ized open label trial in treatment-naïve patients once-daily 
fosamprenavir boosted with 100 mg ritonavir was compared 
with boosted atazanavir in the ALERT study (Smith et al 
2008). All patients were also treated with a backbone of 
tenofovir and emtricitabine; 106 patients were enrolled and 
48 weeks results provided comparable results for virological 
outcome, CD4 increase, lipid changes, and adverse events. 
Stratiﬁ  cation according to baseline viral load above or below 
100 000 copies/mL did not change the comparison between 
the two arms. In the Context study treatment-experienced 
patients who had a treatment history of one or two protease 
inhibitors and viral load greater than 1000 were randomized 
to either fosamprenavir given once or twice daily or boosted 
lopinavir dosed once daily (DeJesus et al 2003). Patients 
randomized to fosamprenavir once daily received 200 mg of 
ritonavir and for patients on a twice-daily regimen 100 mg of 
ritonavir was given together with 700 mg of fosamprenavir. 
Each regimen was given together with two nucleoside reverse 
transcriptase inhibitors selected according to resistance tests. 
After 24 weeks of treatment non-inferiority was demonstrated 
for both fosamprenavir arms compared to lopinavir according 
to an ITT analysis of time averaged change in vRNA from 
baseline (AAUCMB). A total of 320 patients were enrolled. 
In summary the results are too limited for any conclusions 
on the utility of fosamprenavir given once daily to treatment-
experienced patients, and the regimen is not recommended 
for these patients.
Discussion
Treatment options for HIV patients have dramatically 
improved since the introduction of efﬁ  cacious antiretroviral 
combination therapy more than a decade ago. Treatment 
regimens have been simpliﬁ  ed with fewer pills and fewer 
daily dosages. Fosamprenavir is a PI with a rather long 
half-life that makes it a candidate for once-daily use. 
The rather limited studies published so far indicate that 
fosamprenavir may be used once daily boosted with 
ritonavir. Once-daily fosamprenavir is already listed as 
an alternative treatment in antiretroviral-naïve patients 
according to the Panel on Antiretroviral Guidelines for 
Adults and Adolescents 2008 and in The European AIDS 
Clinical Society (EACS) guidelines. The optimal ritonavir 
dose to be given together with fosamprenavir is, however, 
still to be deﬁ  ned though available results indicate that a 
dose of 100 mg may be adequate, at least in the absence 
of PI resistance.
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